Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomaterials
Main Authors: Zhou, Tian, Su, Hang, Dash, Prasanta, Lin, Zhiyi, Shetty, Bhagya Laxmi Dyavar, Kocher, Ted, Szlachetka, Adam, Lamberty, Benjamin, Fox, Howard S., Poluektova, Larisa, Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Mosley, R. Lee, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5926202/
https://ncbi.nlm.nih.gov/pubmed/29059541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biomaterials.2017.10.023
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki